## Figure 3- source data 1: Reagents used for Figure 3

|  |  |  |
| --- | --- | --- |
| **Drug**  **(molecular weight, kDa)** | **Selectivity** | **Final concentration**  **(duration of superfusion)** |
| **Tyrphostin AG1478** | ErbB1 and ErbB4 inhibitor -  competitively binds to the ATP pocket of ErbB1 and ErbB4 | 10-20 µM  (30 min) |
| **Tyrphostin AG825** | ErbB2 inhibitor -  competitively binds to the ATP pocket of ErbB2 | 50-200 µM  (30 min) |
| **Murine ErbB1-human IgG1Fc chimera**  **(135-150 kDa)** | Blocks activation by EGF, TGFa, AREG or EPGN | 66.7 nM  (90 min) |
| **Human IgG1 Fc**  **(30-35 kDa)** | Control of ErbB1-human IgG1Fc | 286 nM  (90 min) |
| **Murine ErbB4-murine IgG2 Fc chimera**  **(120-140 kDa)** | Blocks activation by HB-EGF, EREG, BTC, NRG3 or NRG4 | 71.4 nM  (90 min) |
| **Murine ErbB3-murine IgG2 Fc chimera**  **(120-135 kDa)** | Blocks activation by  NRG1, NRG2 | 71.4 nM  (90 min) |
| **Murine IgG2a Fc**  **(35 kDa)** | Control of ErbB3 and ErbB4-human IgG2Fc | 286 nM  (90 min) |
| **Heparin** | competitively inhibits HB-EGF binding to its co-receptor heparan sulfate proteoglycan | 40 UI/ ml  (90 min) |
| **p21 peptide**  **(2.1 kDa)** | competitively inhibits HB-EGF binding to its co-receptor heparan sulfate proteoglycan | 12 µM  (90 min) |
| **p21mut peptide**  **(2.1 kDa)** | Inactive version of the p21 peptide | 12 µM  (90 min) |